Bibliografia

Bibliografia

❖ Abbate A, Biondi-Zoccai GG, Agostoni P, Lipinski MJ, Vetrovec GW. Recurrent angina after coronary revascularization: a clinical challenge. Eur Heart J. 2007 May;28(9):1057-65. doi: 10.1093/eurheartj/ehl562. Epub 2007 Mar 23. PMID: 17384090. ❖ Agarwal S, Schechter C, Zaman A. Assessment of functional status and quality of life after percutaneous coronary revascularisation in octogenarians. Age and Ageing. 2009;38(6):748-51. ❖ Al-Lamee RK, Nowbar AN, Francis DP. Percutaneous coronary intervention for stable coronary artery disease.

Heart. 2019 Jan;105(1):11-19. doi: 10.1136/heartjnl-2017-312755. Epub 2018 Sep 21. PMID: 30242142. ❖ Allan Davies, Kim Fox, Alfredo R Galassi, Shmuel Banai, Seppo Ylä-Herttuala, Thomas F Lüscher, Management of refractory angina: an update, European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 269–283, https://doi.org/10.1093/eurheartj/ehaa820 ❖ Anna Palmisano et al. “Feature tracking and mapping analysis of myocardial response to improved perfusion reserve in patients with refractory angina treated by coronary sinus Reducer implantation: a CMR study” The

Int. J. of Cardiovascular Imaging Accepted: 6 August 2020 ❖ Aranda JM Jr, Hill J. Cardiac transplant vasculopathy. Chest. 2000 Dec;118(6):1792-800. doi: 10.1378/chest.118.6.1792. PMID: 11115475. ❖ Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, et al. Effects of Enhanced External

Counterpulsation on Health-Related Quality of Life Continue 12 Months After Treatment: A Substudy of the

Multicenter Study of Enhanced External Counterpulsation, 2002). ❖ Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, et al. Effects of Enhanced External

Counterpulsation on Health-Related Quality of Life Continue 12 Months After Treatment: A Substudy of the

Multicenter Study of Enhanced External Counterpulsation. Journal of Investigative Medicine. 2002;50(1):25. ❖ Banai S, Ben Muvhar S, Parikh KH, Medina A, Sievert H, Seth A, et al. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility firstin-man study. J Am Coll Cardiol. 2007;49(17):1783-9. ❖ Bazoukis G, Brilakis ES, Tse G, Letsas KP, Kitsoulis P, Liu T, et al. The efficacy of coronary sinus reducer in patients with refractory angina-A systematic review of the literature. J. 2018;31(6):775-9. ❖ Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, Ponder KP, Roberts WC, Rosenfeld

HM, Giugliani R. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011 Dec;34(6):1183-97. doi: 10.1007/s10545-011-9359-8. Epub 2011 Jul 9. PMID: 21744090; PMCID: PMC3228957. ❖ Bugiardini R, Bairey Merz CN. Angina with "normal" coronary arteries: a changing philosophy. JAMA. 2005 Jan 26;293(4):477-84. doi: 10.1001/jama.293.4.477. PMID: 15671433. ❖ Cannon RO 3rd, Epstein SE. "Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol. 1988 Jun 1;61(15):1338-43. doi: 10.1016/0002-9149(88)91180-0. PMID: 3287885. ❖ Carlo Zivelonghi et al. “Coronary sinus Reducer implantation results in improved oxygen kinetics at cardiopulmonary exercise test in patients with refractory angina.” Accepted: 17 February 2020 EuroIntervention 2020; Jaa-735 2020, doi: 10.4244/EIJ-D-19-00766

❖ Carpiuc, K. T., Wingard, D. L., Kritz-Silverstein, D., & Barrett-Connor, E. (2010). The association of angina pectoris with heart disease mortality among men and women by diabetes status: the Rancho Bernardo Study. Journal of women's health (2002), 19(8), 1433–1439. https://doi.org/10.1089/jwh.2009.1649 ❖ Cheng K, Sainsbury P, Fisher M, de Silva R. Management of Refractory Angina Pectoris, 2016 ❖ Cheng, K., Sainsbury, P., Fisher, M., & de Silva, R. (2016). Management of Refractory Angina Pectoris. European cardiology, 11(2), 69–76. https://doi.org/10.15420/ecr.2016:26:1 ❖ Chimenti C, Morgante E, Tanzilli G, Mangieri E, Critelli G, Gaudio C, Russo MA, Frustaci A. Angina in fabry disease reflects coronary small vessel disease. Circ Heart Fail. 2008 Sep;1(3):161-9. doi: 10.1161/CIRCHEARTFAILURE.108.769729. PMID: 19808286. ❖ Corcoran CM, Carrillo F, Fernández-Slezak D, Bedi G, Klim C, Javitt DC, Bearden CE, Cecchi GA. Prediction of

psychosis across protocols and risk cohorts using automated language analysis. World Psychiatry. 2018

Feb;17(1):67-75. doi: 10.1002/wps.20491. PMID: 29352548; PMCID: PMC5775133. ❖ Diagnostic and Interventional Cardiology. Neovasc Receives CE Mark for Refractory Angina Treatment System,.

2011.

❖ Diagnostic and Interventional Cardiology. Neovasc Receives CE Mark for Refractory Angina Treatment

System,. 2011 [cited 2020.19.02]; Available from: https://www.dicardiology.com/content/neovascreceives- cemark-refractory-angina-treatment-system. ❖ Foreman RD, Garrett KM, Blair RW. Mechanisms of cardiac pain. Compr Physiol. 2015 Apr;5(2):929-60. doi: 10.1002/cphy.c140032. PMID: 25880519. ❖ Francesco Giannini, Andrea Aurelio, Alaide Chieffo, Impianto del dispositivo Reducer in seno coronarico: un nuovo trattamento per l’angina refrattaria G Ital Cardiol 2016;17(10 Suppl. 1):3S-9S | doi 10.1714/2372.25470 ❖ Gallone G. et Al. Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients, 2019 ❖ Giannini F, Aurelio A, Jabbour RJ, Ferri L, Colombo A, Latib A. The coronary sinus reducer: clinical evidence and technical aspects, 2017 ❖ Giannini F, Baldetti L, Konigstein M, Rosseel L, Ruparelia N, Gallone G, Colombo A, Banai S, Verheye S. Safety and efficacy of the reducer: A multi-center clinical registry - REDUCE study. Int J Cardiol. 2018 Oct 15;269:40-44. doi: 10.1016/j.ijcard.2018.06.116. Epub 2018 Jun 30. PMID: 29983248. ❖ Giannini F, Baldetti L, Konigstein M, Rosseel L, Ruparelia N, Gallone G, et al. Safety and efficacy of the reducer:

A multi-center clinical registry – REDUCE study. Int J Cardiol. 2018;269:40-4. ❖ Giannini F, Palmisano A, Baldetti L, Benedetti G, Ponticelli F, Rancoita PMV, Ruparelia N, Gallone G, Ancona M,

Mangieri A, Tzanis G, De Cobelli F, Del Maschio A, Colombo A, Esposito A. Patterns of Regional Myocardial

Perfusion Following Coronary Sinus Reducer Implantation: Insights by Stress Cardiac Magnetic Resonance. Circ

Cardiovasc Imaging. 2019 Sep;12(9):e009148. doi: 10.1161/CIRCIMAGING.119.009148. Epub 2019 Aug 27. PMID: 31451003; PMCID: PMC7099839. ❖ Gianpiero D’Amico, Giuseppe Tarantini et al. “Usefulness of Coronary Sinus Reducer Implantation for the

Treatment of Chronic Refractory Angina Pectoris” Am J Cardiol 2021;139:22−27

❖ Gulli G, Cemin R, Pancera P, Menegatti G, Vassanelli C, Cevese A. Evidence of parasympathetic impairment in some patients with cardiac syndrome X. Cardiovasc Res. 2001 Nov;52(2):208-16. doi: 10.1016/s00086363(01)00369-8. PMID: 11684068. ❖ Hajar R. Risk Factors for Coronary Artery Disease: Historical Perspectives. Heart Views. 2017 Jul-Sep;18(3):109114. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_106_17. PMID: 29184622; PMCID: PMC5686931. ❖ Hajar R. Risk Factors for Coronary Artery Disease: Historical Perspectives, 2017 ❖ Henry TD, Satran D, Hodges JS, Johnson RK, Poulose AK, Campbell AR, Garberich RF, Bart BA, Olson RE, Boisjolie

CR, Harvey KL, Arndt TL, Traverse JH. Long-term survival in patients with refractory angina. Eur Heart J. 2013

Sep;34(34):2683-8. doi: 10.1093/eurheartj/eht165. Epub 2013 May 12. PMID: 23671156. ❖ Henry TD, Satran D, Jolicoeur EM. Treatment of refractory angina in patients not suitable for revascularization.

Nat Rev Cardiol. 2014 Feb;11(2):78-95. doi: 10.1038/nrcardio.2013.200. Epub 2013 Dec 24. Erratum in: Nat Rev

Cardiol. 2014 Feb;11(2):i. PMID: 24366073. ❖ Hueb W, Uchida AH, Gersh BJ, Betti RT, Lopes N, Moffa PJ, Ferreira BM, Ramires JA, Wajchenberg BL. Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

Coron Artery Dis. 2007 Feb;18(1):55-9. doi: 10.1097/MCA.0b013e328011c0a9. PMID: 17172931. ❖ Ielasi A, Todaro MC, Grigis G, Tespili M. Coronary Sinus Reducer system™: A new therapeutic option in refractory angina patients unsuitable for revascularization. Int J Cardiol. 2016 Apr 15;209:122-30. doi: 10.1016/j.ijcard.2016.02.018. Epub 2016 Feb 3. PMID: 26889595. ❖ Jolicoeur EM, Cartier R, Henry TD, Barsness GW, Bourassa MG, McGillion M, L'Allier PL. Patients with coronary artery disease unsuitable for revascularization: definition, general principles, and a classification. Can J Cardiol. 2012 Mar-Apr;28(2 Suppl):S50-9. doi: 10.1016/j.cjca.2011.10.015. PMID: 22424284. ❖ Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation. 2005 Jun 7;111(22):2906-12. doi: 10.1161/CIRCULATIONAHA.104.521864. Epub 2005 May 31. PMID: 15927966. ❖ Kharabsheh SM, Al-Sugair A, Al-Buraiki J, Al-Farhan J. Overview of exercise stress testing. Ann Saudi Med. 2006;26(1):1-6. ❖ Kiernan TJ, Yan BP, Ruggiero N, Eisenberg JD, Bernal J, Cubeddu RJ, Witzke C, Don C, Cruz-Gonzalez I, Rosenfield

K, Pomersantev E, Palacios I. Coronary artery perforations in the contemporary interventional era. J Interv

Cardiol. 2009 Aug;22(4):350-3. doi: 10.1111/j.1540-8183.2009.00469.x. PMID: 19453819. ❖ Kim HL, Park KW, Kwak JJ, Kim YS, Sir JJ, Lee SJ, Lee HY, Chang HJ, Kang HJ, Cho YS, Chung WY, Chae IH, Choi

DJ, Kim HS, Oh BH, Park YB, Koo BK. Stent-related cardiac events after non-cardiac surgery: drug-eluting stent vs. bare metal stent. Int J Cardiol. 2008 Jan 24;123(3):353-4. doi: 10.1016/j.ijcard.2006.11.182. Epub 2007 Mar 8.

PMID: 17346821. ❖ Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al.: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology, 2019 ❖ Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;41(3):407-77.

❖ Konigstein M, Bazan S, Revivo M, Banai S. Coronary Sinus Reducer implantation improves symptoms, ischaemia and physical capacity in patients with refractory angina unsuitable for myocardial revascularisation: a singlecentre experience. EuroIntervention. 2018;14(4):e452-e8. ❖ Konigstein M, Giannini F, Banai S. The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives, 2018 ❖ Konigstein M, Giannini F, Banai S. The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives. Eur Heart J. 2018;39(11):925-33. ❖ Konigstein M, Meyten N, Verheye S, Schwartz M, Banai S. Transcatheter treatment for refractory angina with the Coronary Sinus Reducer. EuroIntervention. 2014;9(10):1158-64. ❖ Lanza GA, Pasceri V, Colonna G, Cucinelli F, Fortini A, Lanzone A, Crea F, Maseri A. Cardiac autonomic function

and sensitivity to pain in postmenopausal women with angina and normal coronary arteries. Am J Cardiol. 1997

May 1;79(9):1174-9. doi: 10.1016/s0002-9149(97)00077-5. PMID: 9164880. ❖ Lozano I, Capin E, Lee Hwang DH, Lopez-Palop R, Segovia E. Coronary Sinus Reducer Implantation: Potential

New Horizons Where it Should Be Tested, 2018 ❖ Luke K. Kim, Dmitriy N. Feldman, Rajesh V. Swaminathan, Robert M. Minutello, Jake Chanin, David C. Yang, Min

Kyeong Lee, Konstantinos Charitakis, Ashish Shah, Ryan K. Kaple, Geoffrey Bergman, Harsimran Singh, S. Chiu

Wong, Rate of Percutaneous Coronary Intervention for the Management of Acute Coronary Syndromes and

Stable Coronary Artery Disease in the United States (2007 to 2011), The American Journal of Cardiology, Volume 114, Issue 7, 2014, Pages 1003-1010, ISSN 0002-9149, https://doi.org/10.1016/j.amjcard.2014.07.013. ❖ M.J Silvis et al. “The Coronary Sinus Reducer; 5-year Dutch experience” Neth Heart J Accepted: 10 November 2020

❖ Maayan Konigstein et al. “Long-term outcomes of patients undergoing coronary sinus reducer implantation - A multicenter study” Clin Cardiol. 2021 ❖ Maayan Konigstein, Francesco Giannini, Shmuel Banai, The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives, European Heart Journal, Volume 39, Issue 11, 14 March 2018, Pages 925–933, https://doi.org/10.1093/eurheartj/ehx486 ❖ Marwick TH. Stress echocardiography. Heart (British Cardiac Society). 2003;89(1):113-8 ❖ McGillion M, Arthur HM, Cook A, Carroll SL, Victor JC, L'allier PL, Jolicoeur EM, Svorkdal N, Niznick J, Teoh K,

Cosman T, Sessle B, Watt-Watson J, Clark A, Taenzer P, Coyte P, Malysh L, Galte C, Stone J; Canadian

Cardiovascular Society; Canadian Pain Society. Management of patients with refractory angina: Canadian

Cardiovascular Society/Canadian Pain Society joint guidelines. Can J Cardiol. 2012 Mar-Apr;28(2 Suppl):S20-41. doi: 10.1016/j.cjca.2011.07.007. PMID: 22424281. ❖ Michelle M. Graham, R.Jane Chambers, Richard F. Davies, Angiographic quantification of diffuse coronary artery disease: Reliability and prognostic value for bypass operations, The Journal of Thoracic and Cardiovascular

Surgery, Volume 118, Issue 4, 1999, Pages 618-627, ISSN 0022-5223, https://doi.org/10.1016/S0022-5223(99)70006-

1.

❖ Morrison DA, Sethi G, Sacks J, Henderson W, Grover F; Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a

multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the

Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol. 2001

Jul;38(1):143-9. doi: 10.1016/s0735-1097(01)01366-3. PMID: 11451264. ❖ Neovasc I. Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer™. 2020 [cited 2020.19.02.]; Available from: https://www.neovasc.com/newsreleases/neovascs-tiara-fortreatment- of-mitralregurgitation-and-neovasc-reducer-for-treatment-of-refractory-anginafeatured-in-multiple-presentations-attct-2019-conference-2-2-2-3-2-2-2-2-2-2-2-2-2-3-2/. ❖ Pan HL, Chen SR. Sensing tissue ischemia: another new function for capsaicin receptors? Circulation. 2004 Sep 28;110(13):1826-31. doi: 10.1161/01.CIR.0000142618.20278.7A. Epub 2004 Sep 13. PMID: 15364816. ❖ Park KE, Conti CR. Non-PCI/CABG therapies for refractory angina. Trends in Cardiovascular Medicine, 2018 ❖ Paz Y, Shinfeld A. Re: "Transcatheter treatment for refractory angina with the coronary sinus Reducer" by

Maayan Konigstein et al. EuroIntervention. 2015 Oct;11(6):727. doi: 10.4244/EIJY14M07_15. PMID: 25033103. ❖ Paz Y, Shinfeld A. Re: “Transcatheter treatment for refractory angina with the coronary sinus Reducer”, 2015 ❖ Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, Johnson BD, Sopko G, Bairey Merz CN.

Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome

Evaluation) study. J Am Coll Cardiol. 2010 Jun 22;55(25):2825-32. doi: 10.1016/j.jacc.2010.01.054. PMID: 20579539;

PMCID: PMC2898523. ❖ Ponticelli F, Tzanis G, Gallone G, Baldetti L, Mangieri A, Colombo A, et al. Safety and efficacy of Coronary Sinus

Reducer implantation at 2-year follow-up. Int J Cardiol. 2019;292:87-90. ❖ Povsic TJ, Broderick S, Anstrom KJ, et al. Predictors of long‐term clinical endpoints in patients with refractory

angina, 2015 ❖ Povsic TJ, Broderick S, Anstrom KJ, Shaw LK, Ohman EM, Eisenstein EL, Smith PK, Alexander JH. Predictors of long-term clinical endpoints in patients with refractory angina. J Am Heart Assoc. 2015 Jan 30;4(2):e001287. doi: 10.1161/JAHA.114.001287. PMID: 25637344; PMCID: PMC4345862. ❖ Reynolds MW, Frame D, Scheye R, Rose ME, George S, Watson JB, et al. A systematic review of the economic burden of chronic angina, 2004 ❖ Rosen SD, Paulesu E, Frith CD, Frackowiak RS, Davies GJ, Jones T, Camici PG. Central nervous pathways mediating angina pectoris. Lancet. 1994 Jul 16;344(8916):147-50. doi: 10.1016/s0140-6736(94)92755-3. PMID: 7912763. ❖ Rosen SD, Paulesu E, Wise RJ, Camici PG. Central neural contribution to the perception of chest pain in cardiac syndrome X. Heart. 2002 Jun;87(6):513-9. doi: 10.1136/heart.87.6.513. PMID: 12010930; PMCID: PMC1767119. ❖ Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of

Cardiovascular Diseases for 10 Causes, 2015 ❖ Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, et al, Global, Regional, and National Burden of

Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017 Jul 4;70(1):1-25. doi: 10.1016/j.jacc.2017.04.052. Epub 2017 May 17. PMID: 28527533; PMCID: PMC5491406.

❖ Sabik JF 3rd, Lytle BW, Blackstone EH, Houghtaling PL, Cosgrove DM. Comparison of saphenous vein and internal thoracic artery graft patency by coronary system. Ann Thorac Surg. 2005 Feb;79(2):544-51; discussion 544-51. doi: 10.1016/j.athoracsur.2004.07.047. PMID: 15680832. ❖ Sara JD, Widmer RJ, Matsuzawa Y, Lennon RJ, Lerman LO, Lerman A. Prevalence of Coronary Microvascular

Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery Disease. JACC Cardiovasc

Interv. 2015 Sep;8(11):1445-1453. doi: 10.1016/j.jcin.2015.06.017. PMID: 26404197. ❖ Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T;

Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001 Apr 4;285(13):1711-8. doi: 10.1001/jama.285.13.1711. PMID: 11277825. ❖ Sedlis SP, Morrison DA, Lorin JD, Esposito R, Sethi G; Investigators of the Dept. of Veterans Affairs Cooperative

Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol. 2002 Nov 6;40(9):1555-66. doi: 10.1016/s0735-1097(02)02346-x. PMID: 12427406. ❖ Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M,

Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by denovo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015 Jan 3;385(9962):43-54. doi: 10.1016/S01406736(14)61455-0. Epub 2014 Sep 14. PMID: 25230593. ❖ Sestito A, Lanza GA, Le Pera D, De Armas L, Sgueglia GA, Infusino F, Miliucci R, Tonali PA, Crea F, Valeriani M.

Spinal cord stimulation normalizes abnormal cortical pain processing in patients with cardiac syndrome X. Pain. 2008 Sep 30;139(1):82-89. doi: 10.1016/j.pain.2008.03.015. Epub 2008 Apr 28. PMID: 18440702. ❖ Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):15S-22S. doi: 10.1016/s0735-1097(02)02834-6. PMID: 12644336. ❖ Shmuel Bana et al. Coronary Sinus Reducer Stent forthe Treatment of Chronic Refractory Angina Pectoris, 2007 ❖ Simons M, Laham RJ. New therapies for angina pectoris, 2019 ❖ Smith PK, Califf RM, Tuttle RH, Shaw LK, Lee KL, Delong ER, Lilly RE, Sketch MH Jr, Peterson ED, Jones RH.

Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac

Surg. 2006 Oct;82(4):1420-8; discussion 1428-9. doi: 10.1016/j.athoracsur.2006.04.044. PMID: 16996946. ❖ Stanak M., Rothschedl E Percutaneous Transvascular Implantation of a Coronary Sinus Reducing Stent. Decision

Support Document No. 121; 2020. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment ❖ Stefan Verheye et al. “Coronary Sinus Narrowing for the Treatment of Refractory Angina A Multi-Center

Prospective Open-Label Clinical Study (The REDUCER-I Study)” EuroIntervention 2020 Dec 15; EIJ-D-20-00873 ❖ Subramanian S, Sabik JF 3rd, Houghtaling PL, Nowicki ER, Blackstone EH, Lytle BW. Decision-making for patients with patent left internal thoracic artery grafts to left anterior descending. Ann Thorac Surg. 2009

May;87(5):1392-8; discussion 1400. doi: 10.1016/j.athoracsur.2009.02.032. PMID: 19379872.

❖ Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years. Ann Thorac Surg. 2004 Jan;77(1):93-101. doi: 10.1016/s0003-4975(03)01331-6. PMID: 14726042. ❖ Tzanis G, Palmisano A, Gallone G, Ponticelli F, Baldetti L, Esposito A, et al. The impact of the coronary sinus reducer upon left ventricular function in patients with refractory angina pectoris. Catheter Cardiovasc Interv [Internet]. 2019 Aug 02. ❖ Verheye S, Jolicoeur EM, Behan MW, Pettersson T, Sainsbury P, Hill J, et al. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015;372(6):519-27. ❖ W.C. Stanley, Changes in cardiac metabolism: a critical step from stable angina to ischaemic cardiomyopathy, European Heart Journal Supplements, Volume 3, Issue suppl_O, November 2001, Pages O2–

O7, https://doi.org/10.1016/S1520-765X(01)90147-6 ❖ Williams B, Menon M, Satran D, Hayward D, Hodges JS, Burke MN, Johnson RK, Poulose AK, Traverse JH, Henry

TD. Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv. 2010 May 1;75(6):886-91. doi: 10.1002/ccd.22431. PMID: 20432394.